Home     Site Map     Privacy & Terms


Letter from the CEO

Corporate Governance

    Management Team

    Board of Directors

Stock Information

SEC Filings

Corporate Presentations

Annual Reports

Investor Events

News

Analyst Coverage

 

 News

1.25.2012
SANUWAVE Technology Shown to Promote Fracture Healing by Affecting Growth of New Blood Vessels and Bone

1.17.2012
SANUWAVE Issued U.S. Patent for a New Method to Produce Acoustic Shock Waves Utilizing Pressurized Fluid

1.10.2012
PACE Technology Shown to Protect Tissues Against Ischemic and Reperfusion Injury

1.6.2012
SANUWAVE Issued U.S. Patent for the Application of Acoustic Shock Waves Utilizing its PACE Devices

12.21.2011
SANUWAVE Updates on FDA Review of dermaPACE Premarket Approval Application

12.13.2011
SANUWAVE Technology Shown to Proliferate Adult Stem Cells

11.17.2011
SANUWAVE’s dermaPACE Clinical Trial Results Highlighted in CME Presentation at Desert Foot Congress

11.14.2011
SANUWAVE Health Reports Third Quarter Financial Results

10.12.2011
SANUWAVE dermaPACE Technology Shown Superior to Hyperbaric Oxygen Therapy in Increasing Angiogenic and Tissue Regenerative Molecular Changes in Diabetic Foot Ulcers

9.29.2011
SANUWAVE Appoints Private Equity Veteran Barbara M. Henagan to Board of Directors

9.22.2011
dermaPACE Pivotal Phase III Clinical Trial Data in Diabetic Foot Ulcer Healing to be Presented at Plastic Surgery 2011

9.21.2011
SANUWAVE Appoints Medical Technology Veteran Ron Sparks to Board of Directors

9.7.2011
SANUWAVE to Present at the Rodman & Renshaw 13th Annual Global Investment Conference

8.23.2011
SANUWAVE Health Granted U.S. Patent on Use of Acoustic Shock Waves to Treat Orthopedic Conditions

8.10.2011
SANUWAVE Health Reports Second Quarter Financial Results and Provides Business Update

7.27.2011
Positive Data Demonstrating dermaPACE® Safely Heals Diabetic Foot Ulcers to be Highlighted in CME Presentation at The American Podiatric Medical Association Meeting

7.19.2011
SANUWAVE Announces American Medical Association Approval of CPT Category III Codes for Extracorporeal Shock Wave Technology in Wound Healing

7.12.2011
SANUWAVE Announces Positive 24-week Data From its Pivotal Trial Investigating the Use of dermaPACE for the Treatment of Diabetic Foot Ulcers

7.6.2011
SANUWAVE Health Submits Final Module of PMA Application for FDA Approval of dermaPACE® To Treat Diabetic Foot Ulcers

7.5.2011
PACE® Technology Research Conducted at Cleveland Clinic Presented at the 2011 World Congress of Microsurgery

Archives:
2011, 2010, 2009, 2008
12.15.2010
SANUWAVE Announces Positive Top-Line Data from its Pivotal Trial Investigating the Use of dermaPACE for the Treatment of Diabetic Foot Ulcers


6.14.2011
SANUWAVE in the News: The Gray Sheet® Interviews Christopher M. Cashman, President and CEO of SANUWAVE

6.14.2011
U.S. Patent and Trademark Office Upholds Patentability Following an Ex Parte Reexamination Request

6.9.2011
SANUWAVE Extracorporeal Shock Wave Technology Shown to Prevent and Repair Osteoarthritis Damage in Preclinical Model

5.16.2011
SANUWAVE Health Reports First Quarter Financial Results

4.12.2011
dermaPACE® Pivotal Phase III Clinical Trial Results for Diabetic Foot Ulcer Treatment to be Presented at the Symposium on Advanced Wound Care (SAWC) Spring 2011

4.5.2011
SANUWAVE Health Raises $9.1 Million in Private Placement

3.28.2011
SANUWAVE Health Reports 2010 Financial Results

3.16.2011
Study Shows dermaPACE is More Effective than Hyperbaric Oxygen Therapy in DFU

3.9.2011
SANUWAVE Health to Present at Roth Capital Partners 23rd Annual OC Growth Stock Conference

2.7.2011
SANUWAVE Health Raises $4.1 Million

1.25.2011
SANUWAVE Health Granted U.S. Patent on Use of Piezoelectric Fibers to Produce Acoustic Energy in the Shock Wave Spectrum

1.6.2011
SANUWAVE Health Submits to FDA Second Module of PMA Application for dermaPACE for the Treatment of Diabetic Foot Ulcers
12.10.2010
SANUWAVE Health Submits to FDA First Module of PMA Application for dermaPACE for the Treatment of Diabetic Foot Ulcers

11.12.2010
SANUWAVE Health Reports Third Quarter Financial Results and Provides Business Update

10.19.2010
Cleveland Clinic Researchers Publish Data in The Journal of Trauma that Demonstrate Multiple Proangiogenic Mechanisms of SANUWAVE's PACE® Technology

9.21.2010
SANUWAVE Completes Patient Follow Up in Phase III Trial of dermaPACE for the Treatment of Diabetic Foot Ulcers

9.07.2010
SANUWAVE Health to Present at the Rodman & Renshaw Annual Global Investment Conference

8.16.2010
SANUWAVE to Present Newest Device, Profile™, at the 20th Biennial Congress of the International Society of Aesthetic Plastic Surgery

8.13.2010
SANUWAVE Health Reports Second Quarter Financial Results and Provides Business Update

8.03.2010
SANUWAVE's PACE Technology Highlighted in Journal of Surgical Research

7.20.2010
SANUWAVE Health Granted European Patent

7.15.2010
SANUWAVE Health, Inc. Announces LHA Life Sciences & Med Tech Day 2010 Presentation

7.14.2010
SANUWAVE Health Announces European Launch of orthoPACE® Regenerative Medicine Device for Orthopedic Indications

6.7.2010
SANUWAVE Health Presents at the Sixth Annual Noble Financial Equity Conference (Click Here for Link to Recorded Presentation)

5.25.2010
SANUWAVE Health to Present at the Sixth Annual Noble Financial Equity Conference on June 7, 2010

5.14.2010
SANUWAVE Health Reports First Quarter Financial Results and Provides Business Update

4.6.2010
SANUWAVE Completes Enrollment in dermaPACE Phase III Pivotal IDE Clinical Trial for the Treatment of Diabetic Foot Ulcers

3.31.2010
SANUWAVE Health Reports on 2009 Financial Results and Progress for the Year

3.10.2010
SANUWAVE Technology Shown to Successfully Treat Nonunion Fractures of the Tibia

3.4.2010
SANUWAVE's President and CEO, Christopher M. Cashman, to Present at ROTH Capital Partners 22nd Annual OC Growth Stock Conference on March 17, 2010

2.9.2010
PACE Reported to Heal Severe Burns without Surgery or Skin Grafting - U.S. Clinical Trial Expected, and European Distribution Partnerships Planned

1.26.2010
SANUWAVE's PACE Technology Shows Improved Skin Flap Survival Rates In Peer Reviewed Journal Article

1.11.2010
Dr. Maria Siemionow, World Renowned Plastic Surgeon, Joins SANUWAVE's Scientific Advisory Board

1.5.2010
SANUWAVE Health To Present At Sidoti & Company's Micro Cap Conference On January 11, 2010

12.15.2009
The Microcirculatory Effects of SANUWAVE's PACE Technology Explained in Presentation by Joanna Cwykiel of Cleveland Clinic during 10th Annual Wound Healing: Science and Industry Meeting

12.08.2009
The Wall Street Transcript's Interview with Christopher M. Cashman, CEO

11.17.2009
SANUWAVE Hires Vice President of Sales and Marketing, Medical Policy and Reimbursement

11.16.2009
SANUWAVE Health Reports 2009 Third Quarter Results

11.12.2009
SANUWAVE's Stock Symbol Changes to "SNWV" Effective November 12, 2009

10.16.2009
Barry Jenkins, SANUWAVE's Chief Financial Officer, Interviewed by CFO.com Magazine

10.13.2009
SANUWAVE'S PACE Shows Promise In Stimulating Autogenous Sources Of Progenitor/STEM Cells For Harvest And Re-Transplantation In Bone Tissue Engineering

09.30.2009
SANUWAVE, Inc. Becomes a Public Company Through a Reverse Merger with a Subsidiary of Rub Music Enterprises, Inc.

08.19.2009
SANUWAVE, Inc. Adds Southern Arizona VA Medical Center to its dermaPACE Investigational Device Exemption Clinical Trial for Diabetic Foot Ulcers

06.03.2009
SANUWAVE, Inc. Announces the Completion of its Sale of the VersaTron Veterinary Business to Pulse Veterinary Technologies, LLC.

03.30.2009
SANUWAVE, Inc. Announces 100th Patient Has Enrolled in the dermaPACE Investigational Device Exemption (IDE) Clinical Trial

01.29.2009
Oscar Alvarez, PhD conducted a presentation entitled, Shock Wave Therapy, at the 9th Annual Wound Healing: Science and Industry conference held December 12th through 14th in St. Thomas, U.S. Virgin Islands

11.19.2008
A study regarding the mechanism of action of PACE Technology has been completed by Dr. Maria Sieminow of the Cleveland Clinic

09.12.2008
SANUWAVE launches dermaPACE.com to support the dermaPACE Wound Treatment Phase III Clinical Trial

08.01.2008
Latest SANUWAVE Newsletter celebrates the 1st year of dermaPACE wound treatment in Europe, highlights veterinary advances in arthritis treatment and discusses recent ESWT clinical publications regarding patellar tendinopathy and hip necrosis

07.03.2008
SANUWAVE Sponsors Podiatry Management’s Hall of Fame Luncheon Honoring David G. Armstrong, DPM, PhD, and Faye Frankfort, APMA’s Director of Legislative Advocacy on Friday, July 25, 2008, noon–1:00 PM at the Hawaii Convention Center during this year's American Podiatric Medical Association's (APMA) Annual Meeting.

05.14.2008
dermaPACE Used to Successfully Treat Diabetic Foot Ulcers Reported by Kristien Van Acker, MD, PhD et al at the EWMA 2008 Meeting

05.01.2008
American Academy of Orthopaedic Surgeons Honors Dr. Ching-Jen Wang for Best Poster in the Metabolic Disease Category for 2008 titled, "Extracorporeal Shockwave Treatment for Chronic Diabetic Foot Ulcers"

2007, 2006, 2005
07.30.2007
SANUWAVE announces conditional FDA approval of an IDE clinical trial for dermaPACE in the US.

04.27.2007
SANUWAVE Annouces the launch of dermaPACE wound treatment device in Europe

09.18.2006
SANUWAVE Annouces Collaborative Effort with the Cleveland Clinic

09.07.2006
SANUWAVE Announces Acquisition of HMT Japan

07.26.2006
SANUWAVE launches new Web site!

01.10.2006
SANUWAVE names Christopher M. Cashman Chief Executive Officer, Industry Veteran Further Enhances Management Team

08.02.2005
HealthTronics sells its Orthopaedic ESWT Business for $10.4 Million


Copyright © 2006-2012 SANUWAVE, Inc. All Rights Reserved. OssaTron, EvoTron, VersaTron, dermaPACE, OrthoTripsy, “Healing Today. Curing Tomorrow.” and Pulsed Acoustic Cellular Expression (PACE) are all registered trademarks of SANUWAVE.